CYP2C19 loss-of-function carriers have increased risk of cardiac, but not limb, events following clopidogrel treatment for peripheral artery disease revascularization

JVS-Vascular Insights · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles